Device Trial Radar · NCT07856082
Opt-IVF for Personalized Medicine for Normal Responders
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Mar 31, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Urmila DIwekarNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 20 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical trial will determine the effectiveness of the Opt-IVF decision-support tool in generating personalized, optimal drug-dosage profiles for each patient in the United States.
Conditions
- Ivf
Interventions
Opt-IVFDevice
Opt-IVF predicted dosage for IVF
controlOther
Doctor prescribed dosage
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Gonadotropin dosageTime frame: 11 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ABC IVF
West Palm Beach, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.